SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
Company: BioSig Technologies, Inc. (BSGM), a Delaware corporation and emerging growth company.
Reporting Date: September 5, 2019.
Subject: Entry into a material definitive agreement and unregistered sales of equity securities involving NeuroClear Technologies, Inc., a wholly-owned subsidiary of BioSig.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of NeuroClear common stock to an accredited investor.
- Shares Sold (Current): 32,000 shares at $5.00 per share.
- Proceeds (Current): $160,000.
- Recent Prior Transaction: 707,000 shares sold in August 2019 at $5.00 per share for $3,535,000.
- Total Seed Round Raised: Approximately $3.7 million (as announced in the press release).
- Financial Statements: This filing does not provide consolidated revenue, profit, cash flow, or debt metrics for BioSig Technologies, Inc.
Material Changes and Contractual Terms
The filing details a Securities Purchase Agreement containing a specific "Share Exchange" provision:
- Trigger Events: If NeuroClear common stock is not listed on a national securities exchange by October 31, 2020, or if a change of control occurs (whichever is earlier).
- Exchange Ratio: At the investor's option, each share of NeuroClear common stock may be exchanged for 0.9 shares of BioSig Technologies, Inc. common stock.
- Regulatory Status: The offering was conducted under Section 4(a)(2) and Regulation D (Rule 506) exemptions from registration.
Outlook, Risks, and Management Commentary
Management Commentary: The Company announced the completion of NeuroClear's initial seed round, raising approximately $3.7 million.
Risks and Contingencies: The Share Exchange provision creates a potential future dilution event for BioSig shareholders if NeuroClear fails to achieve a public listing by the specified deadline or undergoes a change of control. The filing does not provide specific forward-looking guidance on revenue or earnings.
Key Facts for Investor Verification
- Verify the total capital raised by NeuroClear ($3.7M) and the remaining capital requirements for operations.
- Monitor the October 31, 2020 deadline for NeuroClear's listing on a national securities exchange to assess the risk of the 0.9:1 share exchange.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for additional covenants or obligations.
- Confirm the impact of the potential share exchange on BioSig's existing capital structure and earnings per share.